GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Easywell Biomedicals Inc (ROCO:1799) » Definitions » EBIT

Easywell Biomedicals (ROCO:1799) EBIT : NT$-153.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Easywell Biomedicals EBIT?

Easywell Biomedicals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was NT$-50.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-153.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Easywell Biomedicals's annualized ROC % for the quarter that ended in Mar. 2024 was -25.16%. Easywell Biomedicals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -31.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Easywell Biomedicals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1.20%.


Easywell Biomedicals EBIT Historical Data

The historical data trend for Easywell Biomedicals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easywell Biomedicals EBIT Chart

Easywell Biomedicals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -249.90 -166.75 -153.58 -151.03 -150.65

Easywell Biomedicals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.33 -21.91 -31.33 -49.08 -50.63

Competitive Comparison of Easywell Biomedicals's EBIT

For the Medical Devices subindustry, Easywell Biomedicals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Easywell Biomedicals's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Easywell Biomedicals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Easywell Biomedicals's EV-to-EBIT falls into.



Easywell Biomedicals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-153.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Easywell Biomedicals  (ROCO:1799) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Easywell Biomedicals's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-211.36 * ( 1 - -0.12% )/( (833.917 + 848.428)/ 2 )
=-211.613632/841.1725
=-25.16 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1213.784 - 31.837 - ( 348.03 - max(0, 127.567 - 507.635+348.03))
=833.917

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1388.241 - 30.516 - ( 509.297 - max(0, 137.358 - 661.48+509.297))
=848.428

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Easywell Biomedicals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-202.516/( ( (548.032 + max(84.667, 0)) + (571.56 + max(77.938, 0)) )/ 2 )
=-202.516/( ( 632.699 + 649.498 )/ 2 )
=-202.516/641.0985
=-31.59 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(65.046 + 42.171 + 49.122) - (31.837 + 0 + 39.835)
=84.667

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(48.577 + 60.744 + 37.973) - (30.516 + 0 + 38.84)
=77.938

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Easywell Biomedicals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-152.955/12704.281
=-1.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Easywell Biomedicals EBIT Related Terms

Thank you for viewing the detailed overview of Easywell Biomedicals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Easywell Biomedicals (ROCO:1799) Business Description

Traded in Other Exchanges
N/A
Address
No.10, Yanfa 2nd Rd, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076
Easywell Biomedicals Inc is engaged in the design, manufacture, and sales of thermometers for measuring body temperature and other medical instruments such as digital clinical thermometers, infrared ear thermometers, probe covers, and blood/urine/total cholesterol metabolites monitoring systems, among others. It has a Drug development segment and Other segments.

Easywell Biomedicals (ROCO:1799) Headlines

No Headlines